2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1618

The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA
Abstract Number: 1619

Genetic Influences of Susceptibility to Rheumatoid Arthritis in African Americans
Abstract Number: 1620

DNA Methylation Profiling of Rheumatoid Arthritis Peripheral Blood Identifies Hypermethylation of TRIM69 Promoter Region in CD4+ T Cells Associated with Disease Activity
Abstract Number: 1621

Genetic Contributions to Radiographic Damage in African Americans with Rheumatoid Arthritis on a Panel of Autoimmune Disease Markers
Abstract Number: 1622

Genome-Wide Association Analysis and Whole Genome Sequencing Identify Variants Associated with Radiographic Severity of Rheumatoid Arthritis in African Americans
Abstract Number: 1623

Genome-Wide Association Study of DNA Methylation in Th1 and Th17 Cells in Rheumatoid Arthritis
Abstract Number: 1624

Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis. Alterations Related to Cardiovascular Disease and Endothelial Dysfunction
Abstract Number: 1625

Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling
Abstract Number: 1626

The Association of HLA-DRB1 Alleles and Amino Acid Residues with Radiographic Severity in African Americans with Seropositive Rheumatoid Arthritis
Abstract Number: 1627

HIF-1alpha Knockdown Down-Regulates Glycolytic Metabolism and Induces Rheumatoid Synovial Fibroblast Cell Death
Abstract Number: 1628

A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis
Abstract Number: 1629

Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Abstract Number: 1630

Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents
Abstract Number: 1631

Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Abstract Number: 1632

Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].